Mucopolysaccharidosis Type 3a has emerging NIH research funding with 1 grant totaling $3.0M.
NIH fiscal year (Oct–Sep)
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Mucopolysaccharidosis Type 3a. Strongest funded area: Gene Therapy / Cell Therapy. Largest gap: Epidemiology / Natural History.
5 clinical trials registered but no NIH-funded clinical or translational research grants found for mucopolysaccharidosis type 3A. Trials may be industry-sponsored or funded through non-NIH sources.
6 publications in Basic Science / Preclinical but no NIH-funded grants found in Basic Science for mucopolysaccharidosis type 3A. Existing research activity suggests this may be a viable area for grant applications.
7 publications in Epidemiology / Natural History but no NIH-funded grants found in Epidemiology / Natural History for mucopolysaccharidosis type 3A. Existing research activity suggests this may be a viable area for grant applications.
Track funding opportunities for Mucopolysaccharidosis Type 3a.
Follow this disease to be notified about new NIH grants and funding changes.
Already have an account? Sign in to manage your watchlists.